Three New Ursane-Type Triterpenoids from the Stems of Saprosma merrillii

Dashuai Zhang 1,†, Wenhao Chen 1,†, Wenxing Chen 2, Xiaoping Song 1, Changri Han 1, Yan Wang 1 and Guangying Chen 1,*

1 Key Laboratory of Tropical Medicinal Plant Chemistry of Ministry of Education, College of Chemistry and Chemical Engineering, Hainan Normal University, Haikou 571158, Hainan, China
2 Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210046, Jiangsu, China

† These authors contributed equally to this work.

* Author to whom correspondence should be addressed; E-Mail: chgying123@163.com; Tel./Fax: +86-898-6588-9422.

Received: 25 September 2013; in revised form: 13 November 2013 / Accepted: 14 November 2013 / Published: 25 November 2013

Abstract: Three new ursane-type triterpenoids, 3α,6α,30-trihydroxy-ursan-28-oic acid (1), 3α,30-dihydroxy-6-oxo-ursan-28-oic acid (2) and 3α,6α,7α,30-tetrahydroxy-ursan-28-oic acid (3), together with one known triterpenoid, betulinic acid (4), one known anthraquinone, 1,7-dihydroxy-2-methylanthraquinone (5), four known phenols, 1,3,5-trimethoxybenzene (6), p-hydroxybenzoic acid (7), syringic acid (8), isovanillin (9), two steroids, sitosterol (10) and daucosterol (11), were isolated from the ethanol extract of the stems of S. merrillii. Their structures were elucidated on the basis of physical and spectral techniques, besides comparison with literature data. Compounds 1–3 showed inhibitory activities against the A549, HEPG2, and B16F10 cell lines.

Keywords: Saprosma merrillii; bioassay-guided fractionation; triterpenoid; antineoplastic activity

1. Introduction

The genus Saprosma belongs to the family Rubiaceous which has about 50 species found around the world, and has been used as a traditional medicine for the treatment of fever and lumbocural pain [1–6].
Iridoid glycosides [1,2,7], sulfur-containing iridoid glycosides [1,7–9], anthraquinones [3,7,9], and alkaloids [4] have been reported from this genus, and some of these compounds showed good anti-inflammatory, antibacterial and antitumor effect [1–4].

*S. merrillii* is an endemic plant in Hainan Island whose chemical constituents have not been investigated previously. As part of our continuing study on bioactive components from tropical medicinal plants from Hainan, the stems of *S. merrillii* were investigated. The EtOAc soluble fraction of the EtOH extract of *S. merrillii*, which showed cytotoxic activity against the A549 cell line, with an IC₅₀ value of 65.66 μg/mL, was further purified by column chromatography to afford three new ursane-type triterpenoids 1–3 (Figure 1) and eight known compounds 4–11. Here, we wish to report on the isolation and structural elucidation of these compounds. Compounds 1–3 were evaluated for their cytotoxicity against the A549, MDA-MB-231, HEPG2 and B16F10 tumor cell lines.

**Figure 1.** Structures of compounds 1–11.

![Structures of compounds 1–11](image)

2. Results and Discussion

The air-dried stems of *S. merrillii* were extracted three times with 80% EtOH at room temperature. The EtOH extract of the plant was suspended in water and then partitioned successively with petroleum ether and EtOAc. Column chromatography (CC) of the EtOAc-soluble fraction yielded three new compounds 1–3 and eight known compounds 4–11.

Compound 1 was isolated as a white amorphous solid. Its molecular formula was assigned to be C₃₀H₅₀O₅ based on the HRESIMS (m/z: 513.3559 [M+Na]⁺, calcd. for C₃₀H₄₀O₅Na, 513.3551) indicating six degrees of unsaturation. The IR spectrum showed absorption bands for hydroxyl (3,432 cm⁻¹), carbonyl (1,704 cm⁻¹) and C-O (1,040 cm⁻¹) functions, respectively.
| NO. | δ_C  | δ_H  | δ_C  | δ_H  | δ_C  | δ_H  |
|-----|------|------|------|------|------|------|
| 1   | 38.3 t | 1.54 (1H, m, H-1β), 1.63 (1H, m, H-1α) | 34.5 t | 1.47 (1H, m, H-1β), 1.65 (1H, m, H-1α) | 34.2 t | 1.64 (1H, m, H-1β), 1.83 (1H, m, H-1α) |
| 2   | 26.4 t | 1.51 (1H, m, H-1α), 2.05 (1H, m, H-1β) | 26.0 t | 1.56 (1H, m, H-1α), 1.92 (1H, m, H-1β) | 26.6 t | 1.50 (1H, m, H-1α), 2.04 (1H, m, H-1β) |
| 3   | 78.5 d | 3.26 (1H, t, 2.4) | 75.7 d | 3.19 (1H, br s) | 77.0 d | 3.28 (1H, t, 2.6) |
| 4   | 39.4 s | 37.2 s | 39.1 s | 37.2 s |
| 5   | 50.2 d | 1.31 (1H, br.s) | 60.0 d | 2.77 (1H, s) | 48.7 d | 1.41 (1H, br.s) |
| 6   | 69.3 d | 4.34 (1H, m) | 213.7 s | 213.7 s |
| 7   | 42.9 t | 1.50 (1H, m, H-1α), 1.63 (1H, m, H-1β) | 52.8 t | 1.80 (1H, m, H-1α), 2.57 (1H, d, 11.6 H-1β) | 74.6 d | 3.62 (1H, dd, 4.4, 4.8) |
| 8   | 41.3 s | 37.2 s | 37.2 s |
| 9   | 49.8 d | 1.63 (1H, m) | 49.3 d | 1.73 (1H, m) | 49.2 d | 1.70 (1H, m) |
| 10  | 38.0 s | 44.3 s | 44.3 s |
| 11  | 22.1 t | 1.43 (1H, m, H-1α), 1.61 (1H, m, H-1β) | 22.1 t | 1.41 (1H, m, H-1α), 1.66 (1H, m, H-1β) | 21.7 t | 1.39 (1H, m, H-1α), 1.64 (1H, m, H-1β) |
| 12  | 33.2 t | 2.22 (1H, dt, 12.6, 2.8 H-1α) | 32.6 t | 1.48 (1H, m, H-1β), 2.24 (1H, m, H-1α) | 33.1 t | 1.35 (1H, m, H-1β), 2.20 (1H, dt, 12.8, 3.6 H-1α) |
| 13  | 38.8 d | 43.1 d | 2.37 (1H, m) | 38.9 d | 2.41 (1H, dt, 12.8, 3.6) |
| 14  | 43.9 s | 43.8 s | 44.4 s |
| 15  | 31.0 t | 1.17 (1H, m, H-1β), 1.56 (1H, m, H-1α) | 30.4 t | 1.02 (1H, m, H-1β), 1.48 (1H, m, H-1α) | 36.6 t | 1.16 (1H, m, H-1β), 1.34 (1H, m, H-1α) |
| 16  | 28.6 t | 1.34 (1H, m, H-1α), 1.66 (1H, m, H-1β) | 27.6 t | 1.43 (1H, m, H-1α), 1.69 (1H, m, H-1β) | 28.5 t | 1.28 (1H, m, H-1α), 1.66 (1H, m, H-1β) |
| 17  | 57.9 s | 57.0 s | 57.0 s |
| 18  | 51.9 d | 1.54 (1H, m) | 51.0 d | 2.08 (1H, t, 4.0) | 51.6 d | 1.40 (1H, m) |
| 19  | 39.5 d | 1.83 (1H, m) | 38.8 d | 1.86 (1H, m) | 39.3 d | 1.87 (1H, m) |
| 20  | 44.6 d | 2.31 (1H, tt, 10.8, 3.0) | 44.2 d | 2.29 (1H, m) | 44.4 d | 2.30 (1H, m) |
| 21  | 24.7 t | 1.31 (1H, m, H-1α), 1.51 (1H, m, H-1β), 1.30 (1H, m, H-1α), 1.37 (1H, m, H-1β) | 24.4 t | 1.39 (1H, m, H-1α), 1.55 (1H, m, H-1β) | 24.4 t | 1.32 (1H, m, H-1α), 1.54 (1H, m, H-1β) |
| 22  | 36.8 t | 37.7 t | 37.9 t |
| 23  | 28.9 q | 0.98 (3H, s) | 27.4 q | 0.94 (3H, s) | 28.7 q | 0.98 (3H, s) |
| 24  | 24.8 q | 1.20 (3H, s) | 22.6 q | 1.19 (3H, s) | 25.0 q | 1.22 (3H, s) |
| 25  | 15.4 q | 0.99 (3H, s) | 17.4 q | 0.86 (3H, s) | 15.6 q | 1.06 (3H, s) |
| 26  | 17.4 q | 1.28 (3H, s) | 16.5 q | 0.93 (3H, s) | 11.0 q | 1.21 (3H, s) |
| 27  | 18.0 q | 1.23 (3H, s) | 15.1 q | 1.14 (3H, s) | 17.8 q | 1.22 (3H, s) |
| 28  | 180.2 s | 177.7 s | 177.8 s |
| 29  | 18.8 q | 0.96 (3H, d, 6.8) | 18.8 q | 0.93 (3H, d, 7.0) | 18.8 q | 0.94 (3H, d, 6.8) |
| 30  | 64.2 t | 3.75 (1H, dd, 10.6, 4.4, H-1α) | 63.7 t | 3.76 (1H, dd, 10.0, 4.6, H-1α) | 63.8 t | 3.34 (1H, m, H-1α), 3.76 (1H, 10.2, 4.6, H-1β) |

Table 1. NMR data for compounds 1–3 (a in MeOD, b in acetone-d_6, δ in ppm, J in Hz).
The $^1$H-NMR spectrum of 1 showed the following signals: five tertiary methyl groups at $\delta_H$ 1.28, 1.23, 1.20, 0.99 and 0.98 (each 3H, s), a secondary methyl at $\delta_H$ 0.96 (3H, d, $J = 6.8$Hz, H-29), one oxygenated methylene protons $\delta_H$ 3.75 (1H, dd, $J = 10.6, 4.4$ Hz, H-30b), and 3.33 (1H, m, H-30a), two oxygenated methine protons $\delta_H$ 4.34 (1H, m, H-6), 3.26 (1H, t, $J = 2.4$ Hz, H-3) and a series of overlapped signals suggesting an ursane-type triterpenoid. The $^{13}$C-NMR spectrum revealed 30 carbon signals, which were further classified by DEPT and HSQC experiments as six methyls, 10 methylenes (one oxygenated), eight methines (two oxygenated), six quaternary carbons (including one carboxyl group) (Table 1). The aforementioned data implied that 1 was an ursane-28-oic-acid with three hydroxyls [10–15].

In the HMBC spectrum, the oxygenated methylene protons $\delta_H$ 3.75, 3.33 (H$_2$-30) showed correlations to C-19 ($\delta_C$ 39.5), C-20 ($\delta_C$ 44.6) and C-21 ($\delta_C$ 24.7), indicating that one hydroxyl was linked at C-30. Moreover, two oxygenated methine protons $\delta_H$ 4.34 (H-6) and $\delta_H$ 3.26 (H-3), which were deduced by the HMBC correlations from the proton $\delta_H$ 4.34 to C-8 ($\delta_C$ 41.3), C-10 ($\delta_C$ 38.0) and from $\delta_H$ 3.26 to C-5 ($\delta_C$ 50.2), C-23 ($\delta_C$ 28.9) and C-24 ($\delta_C$ 24.8). These observations, together with the HMBC correlations between $\delta_H$ 1.34, 1.66 (H$_2$-16) and 1.30, 1.37 (H$_2$-22) and the carboxyl group $\delta_C$ 180.2 (C-28), were used to establish the molecular framework of 1 (Figure 2).

**Figure 2.** Key $^1$H-$^1$H COSY (bold bonds) and HMBC correlations (arrows) of 1–3.

The relative configuration of 1 was established by analysis of the key correlations displayed in the NOESY spectrum (Figure 3). The key correlation from $\delta_H$ 3.26 (H-3) to 1.20 (H$_3$-24), proves hydrogen of C-3 is $\beta$-orientation. $\delta_H$ 4.34 (H-6) showed correlations to $\delta_H$ 0.99 (H$_3$-25) and 1.28 (H$_3$-26), proves hydrogen of C-6 is $\beta$-orientation. On the basis of the above discussion, the relative configuration of 1 was established as shown (Figure 1). Thus, compound 1 was determined to be 3α,6α,30-trihydroxyursan-28-oic acid.

**Figure 3.** Key NOESY correlations of 1.
Compound 2 was isolated as a white amorphous solid. Its molecular formula was assigned to be C_{30}H_{48}O_{5} based on the HRESIMS, which showed a unit of two hydrogen atoms less than that of compound 1. Its NMR spectra (Table 1 and Experimental Section) were similar to those of 1, except for one oxygenated methine δ_{H} 4.34 (1H, m, H-6), δ_{C} 69.3 (C-6) to the ketone carbon at δ_{C} 213.7 (C-6) in 2. This was supported by the HMBC correlations between δ_{H} 2.77 (H-5), 1.80 and 2.57 (H_{2}-7) and the carbonyl group (Figure 2). The relative configuration of compound 2 was obtained from the NOESY spectrum (Figure 4), the cross-peak between δ_{H} 3.19 (H-3) and 1.19 (H-24) indicated that the configuration of 2 was the same as that shown above for 1, in relevant parts of the molecule. Finally, the structure of 2 was determined to be 3α,30-dihydroxy-6-oxo-ursan-28-oic acid.

![Figure 4. Key NOESY correlations of 2.](image)

Compound 3 was isolated as a white amorphous solid. Its molecular formula was assigned to be C_{30}H_{50}O_{6} based on the HRESIMS, which showed a unit of one oxygen atom more than that of compound 1. Its NMR spectra (Table 1 and Experimental Section) were similar to those of 1, except for one more oxygenated methine δ_{H} 3.62 (1H, t, J = 4.8 Hz, H-7) that showed correlation to δ_{H} 4.11 (H-6) in the ¹H-¹H COSY spectrum fixed its position. In the NOESY spectrum (Figure 5), the key correlations from δ_{H} 4.11 (H-6) to 1.06 (H_{3}-25), δ_{H} 3.62 (H-7) to 1.21 (H_{3}-26), proves hydrogens of C-6 and C-7 are both β-orientation. Thus, the structure of compound 3 was elucidated as 3α,6α,7α,30-tetrahydroxy-ursan-28-oic acid.

![Figure 5. Key NOESY correlations of compound 3.](image)

Compounds 1–3 were evaluated for their anti-proliferative activities against the human lung cancer A549, human breast cancer MDA-MB-231, human hepatocellular carcinoma HEPG2 and mouse melanoma B16F10 cancer cell lines using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay method in vitro [16]. Compound 1 exhibited weak cytotoxicity against the B16F10 cell line, with an IC_{50} value of 72.72 μM, while 2 inhibited the proliferation of the A549 cell line with an IC_{50} value of 24.66 μM (Table 2).
Table 2. Cytotoxic activities of 1–3 against four cancer cell lines.

| Compounds | IC₅₀ (μM) |
|-----------|-----------|
|           | A549      | MDA-MB-231 | HEPG2 | B16F10 |
| 1         | N         | N          | N     | 72.72   |
| 2         | 24.66     | N          | 127.80| N       |
| 3         | 129.22    | N          | N     | N       |

N: means inactive with IC₅₀ values above 150 μM.

3. Experimental

3.1. General

Optical rotations were measured with PolAAR 3005 polarimeter (Optical Activity Limited, Cambridgeshire, UK). IR spectra were recorded on a Thermo Nicolet 6700 (using KBr disks) spectrophotometer (Thermo Scientific, Madison, WI, USA). NMR spectra were acquired on a Bruker AV (400 MHz for 1H-NMR, ppm relative to TMS) spectrometer (Bruker, Hesse-Darmstadt, Germany). ESIMS spectra were recorded on an Agilent 1200 series HPLC (Agilent Technologies, Waldbroon, Germany) interfaced to an Bruker Esquire 6000 Ion Trap mass spectrometer equipped with an electrospray ionization source, and HRESIMS spectra were made on the Bruker Daltonics Apex-Ultra 7.0 T (Bruker Corporation, Billerica, MA, USA), respectively. Column chromatography of silica gel (200–300 mesh), all solvents for column chromatography were of analytical grade (Xilong Chemical Reagents Company, Ltd., Guangdong, China). Spots of compounds on TLC were visualized by spraying using 10% H₂SO₄ in EtOH (v/v) followed by heating.

3.2. Plant Material

*S. merrillii* was collected from Sanya, Hainan Province, China, in August 2009 and was identified by Professor Qiongxin Zhong of School of Life Science, Hainan Normal University. A voucher specimen (No. 200908QDRMS) was deposited at the Department of Key Laboratory of Tropical Medicinal Plant Chemistry of Ministry of Education, Hainan Normal University.

3.3. Extraction and Isolation

The stems of *S. merrillii* was air-dried (9.8 kg) and extracted three times with 80% EtOH (60 L × 3 d each) at room temperature. The EtOH extract (380 g) was suspended in water and then partitioned successively with petroleum ether and EtOAc. The EtOAc-soluble portion (60 g) was subject to Si gel CC (200–300 mesh), eluting with a gradient of mixtures of petroleum ether/EtOAc/MeOH (from 1:0:0 to 0:0:1) to give 10 major fractions (Fr1–Fr10) according to TLC analysis. Fr1 (1.1 g) was recrystallized from EtOAc to afford 10 (0.5 g). Fr2 (0.2 g) was chromatographed on a Si gel column eluted with petroleum ether/EtOAc (from 1:0 to 1:1) to afford 4 (1.5 mg). Fr3 (0.4 g) was chromatographed on a Si gel column eluted with petroleum ether/EtOAc (from 1:0 to 1:2) to afford 5 (2.5 mg) and 6 (2.0 mg). Fr4 (0.5 g) was chromatographed on a silica gel column eluted with petroleum ether/EtOAc (from 1:0 to 1:2) to afford eight major subfractions (Fr4a–Fr4h). Fr4a (0.3 g) was further purified by Si gel column chromatography (petroleum ether/EtOAc, from 1:0 to 1:2) to
obtain 7 (3.0 mg). Fr5 (0.6 g) was chromatographed on Si gel column eluted with petroleum ether/acetone (from 2:1 to 0:1) to afford 8 (3.5 mg). Fr6 (0.5 g) was chromatographed on Si gel column eluted with petroleum ether/CHC13/EtOAc (4:2:1) to afford six major subfractions, Fr6a–Fr6f. Fr6b (0.2 g) was further purified by Si gel (petroleum ether/CHC13/EtOAc, 2:4:1) to obtain 9 (2.0 mg). Fr7 (1.2 g) was chromatographed on Si gel column eluted with petroleum ether/EtOAc (from 1:0 to 0:1), recrystallized from MeOH to afford 1 (53 mg). Fr8 (1.2 g) was chromatographed on Si gel column eluted with petroleum ether/EtOAc (from 1:0 to 0:1), recrystallized from acetone to afford 2 (15 mg). Fr9 (1.2 g) was chromatographed on Si gel column eluted with petroleum ether/EtOAc (from 1:0 to 0:1), recrystallized from acetone to afford 3 (10.0 mg). Fr10 (5.0 g) was recrystallized from MeOH to afford 11 (1.1 g).

3.4. Characterization of Compounds 1–3

Compound 1: white amorphous solid; [α]D 28 −108.33 (c 0.0024, MeOH); IR (KBr) νmax 3432, 2949, 2873, 1704, 1641, 1459, 1383, 1278, 1181, 1040, 990 cm–1; 1H- and 13C-NMR data see Table 1; ESIMS m/z 489.4 [M−H]−, 513.3 [M+Na]+; HRESIMS m/z: 513.3559 [M+Na]+ (calcd for C30H49O5Na, 513.3551).

Compound 2: white amorphous solid; [α]D 28 −20.73 (c 0.0019, MeOH); IR (KBr) νmax 3440, 2948, 2873, 1704, 1636, 1458, 1387, 1174, 1070, 1032, 986, 928 cm–1; 1H- and 13C-NMR data see Table 1; ESIMS m/z 487.6 [M−H]−, 511.5 [M+Na]+; HRESIMS m/z: 511.3389 [M+Na]+ (calcd for C30H48O5Na, 511.3394).

Compound 3: white amorphous solid; [α]D 28 −37.84 (c 0.0037, MeOH); IR (KBr) νmax 3442, 2951, 2875, 1704, 1647, 1458, 1384, 1229, 1176, 1110, 1035, 920 cm–1; 1H- and 13C-NMR data see Table 1; ESIMS m/z: 505.7 [M−H]−, 529.5 [M+Na]+; HRESIMS m/z: 529.3501 [M+Na]+ (calcd for C30H50O6Na, 529.3499).

3.5. Cytotoxicity Assays

Test compounds 1–3 were dissolved in DMSO (final concentration, 0.1%). The cytotoxicity of compounds 1–3 against A549, MDA-MB-231, HEPG2 and B16F10 was determined by standard MTS assay [16]. Cells dispersed evenly in medium and were seeded in a 96-well plate with a density of 1 × 104 cells/well. Next day, cells were treated with various concentrations of samples (0–100 μM) for 48 h or treated with indicated concentrations for 48 h with six replicates of each treatment. After incubation, each well was added 20 μL of MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] reagent and incubated for 3 h. Cell viability was determined by measuring the optical density at 490 nm using a Biotek microplate reader (Biotek, Winooski, VT, USA). Untreated cells in medium were used as control. Corresponding groups without cells were used as blanks. All experiments were carried out with four replicates.
4. Conclusions

In conclusion, our phytochemical investigation of the stems of *S. merrillii* afforded three new triterpenoids: 3α,6α,30-trihydroxy-ursan-28-oic acid (1), 3α,30-dihydroxy-6-oxo-ursan-28-oic acid (2), 3α,6α,7α,30-tetrahydroxy-ursan-28-oic acid (3), together with one known triterpenoid, betulinic acid (4) [17], one known anthraquinone, 1,7-dihydroxy-2-methylanthraquinone (5) [18], four known phenols, 1,3,5-trimethoxybenzen (6) [19], p-hydroxybenzoic acid (7) [20], syringic acid (8) [21], isovanillin (9) [22], two steroids, sitosterol (10) and daucosterol (11). Compound 1 exhibited weak cytotoxicity against the B16F10 cell line with an IC50 value of 72.72 μM, while 2 inhibited the proliferation of the A549 cell line with an IC50 value of 24.66 μM (Table 2).

Acknowledgments

This work was supported financially by the National Natural Science Foundation of China (No. 21162009, 31360069) and 973 Program, Ministry of Science and Technology of China (Grant No. 2011CB512010).

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Ling, S.K.; Komorita, A.; Tanaka, T. Sulfur-containing bis-iridoid glucosides and iridoid glucosides from *Saprosmas cortechinii*. *J. Nat. Prod.* 2002, 65, 656–660.
2. Lu, X.L.; Xin, C.; Liu, X.Y. Iridoid glycosides from *Saprosma ternatum*. *Planta Med.* 2010, 76, 1746–1748.
3. Singh, D.N.; Verma, N.; Raghuwanshi, S. Antifungal anthraquinones from *Saprosma fragrans*. *Bioorg. Med. Chem. Lett.* 2006, 16, 4512–4514.
4. Wang, L.; Chen, G.Y.; Han, C.R.; Yuan, Y.; Yang, B.; Zhang, Y.; Wang, J.; Zhong, X.Q.; Huang, X. Two novel alkaloids from the Stem of *Saprosma hainanense* and their cytotoxic activities *in vitro*. *Chem. Pharm. Bull.* 2011, 59, 338–340.
5. Dai, C.Y.; Yang, B.; Zhang, D.S.; Chen, G.Y.; Han, C.R. Antitumor activities of extracts from *Trigonostemon xyphophylloides* and *Saprosma merrillii*. *J. Hainan Normal Univ. (Nat. Sci.*) 2012, 25, 184–187.
6. Wang, Q.; Lin, H.W.; Shen, Y.; Jin, C.Y. An ke su capsule of antitumor effect. *Zhong Yao Cai* 2000, 23, 634–636.
7. Ling, S.K.; Komorita, A.; Tanaka, T. Iridoids and anthraquinones from the Malaysian medicinal plant, *Saprosma scortechinii* (Rubiaceae). *Chem. Pharm. Bull.* 2002, 50, 1035–1040.
8. Singh, D.N.; Verma, N.; Kulshreshtha, D.K. Sulfur-containing bis-iridoid glucoside from *Saprosma fragrans*. *Ind. J. Heter. Chem.* 2011, 21, 5–8.
9. Singh, D.N.; Verma, N. Iridoid glucosides and anthraquinone from the aerial parts of *Saprosma fragrans*. *J. Ind. Chem. Soc.* 2012, 89, 429–431.
10. Huang, P.L.; Wang, L.W.; Lin, C.N. New triterpenoids of Mallotus repandus. *J. Nat. Prod.* **1990**, *62*, 891–892.

11. Sun, H.X.; Zhang, J.X.; Ye, Y.P.; Shen, Y.A. Cytotoxic pentacyclic triterpenoids from the rhizome of Astilbe chinensis. *Helv. Chim. Acta* **2003**, *86*, 2414–2423.

12. Song, Q.Y.; Qi, W.Y.; Li, Z.M.; Zhao, J.; Chen, J.J.; Gao, K. Antifungal activities of triterpenoids from the roots of Astilbe myriantha Diels. *Phytochemistry* **2011**, *128*, 495–499.

13. Calabria, L.M.; Piacente, S.; Kapusta, I.; Dharmawardhane, S.F.; Segarra, F.M.; Pessiki, P.J.; Mabry, T.J. Triterpene saponins from Silphium radula. *Phytochemistry* **2008**, *69*, 961–972.

14. Song, Y.L.; Wang, Y.H.; Lu, Q.; Qiao, H.J.; Cheng, Y.X. Triterpenoids from the edible leaves of Photinia serrulata. *Helv. Chim. Acta* **2008**, *91*, 665–672.

15. Ghan, W.R.; Sheppard, V.; Medford, K.A.; Tinto, W.F.; Reynolds, W.F.; McLea, S. Triterpenes from Miconia stenostachya. *J. Nat. Prod.* **1992**, *55*, 963–966.

16. Cory, A.H.; Owen, T.C.; Barltrop, J.A.; Cory, J.G. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. *Cancer Commun.* **1991**, *3*, 207–212.

17. Cai, X.H.; Luo, X.D.; Zhou, J.; Hao, X.J. Quinones from Chirita eburnea. *J. Nat. Prod.* **2005**, *68*, 797–799.

18. Zhang, Y.; Deng, Z.W.; Gao, T.X.; Fu, H.; Lin, W. Chemical constituents from the mangrove plant Ceriops tagal. *Acta Pharm. Sin.* **2005**, *40*, 935–939.

19. Liu, Y.B.; Cheng, X.R.; Qin, J.J.; Yan, S.K.; Jin, H.Z.; Zhang, W.D. Chemical Constituents of Toona ciliata var. pubescens. *Chin. J. Nat. Med.* **2011**, *9*, 115–119.

20. Bai, H.; Dou, D.Q.; Pei, Y.P.; Chen, Y.J.; Wu, L.J. Chemical constituents of cultivated Glycyrrhiza uralensis. *Chin. Tradit. Herbal Drug.* **2005**, *36*, 652–654.

21. Zhang, Y.L.; Gan, M.L.; Li, S.; Wang, S.J.; Zhu, C.G.; Hu, J.F.; Chen, N.H.; Shi, J.G. Chemical constituents of stems and branches of Adina polycephala. *Zhongguo Zhong Yao Za Zhi* **2010**, *35*, 1261–1271.

22. Xu, J.J.; Tan, N.H.; Zeng, G.Z.; Han, H.J.; Huang, H.Q.; Ji, C.J.; Zhu, M.J.; Zhang, Y.M. Studies on chemical constituents in fruit of Alpinia oxyphylla. *Zhongguo Zhong Yao Za Zhi* **2009**, *34*, 990–993.

Sample Availability: Samples of the compounds 1–11 are available from the authors.

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).